µCi per mL of [γ32P]-ATP in a total volume of 12 µl. This reaction was carried out for 30 minutes, and was stopped by mixing 5 µl of the reaction mixture with 5 µl of 20 mM EDTA. Then, 2.5 µl of the reaction mixture was spotted on a nitrocellulose membrane. The membrane was washed five times with a 1 M NaCl/1% phosphoric acid solution. After all washes, the membrane was dried, followed by a 30-60 min exposure to a phosphor screen (Molecular Dynamics). The spot intensity on the phosphor screen was imaged using a Typhoon phosphoimager (GE Healthcare). The intensity was quantitated using ImageQuant (GE Healthcare).
Protein-Lipid FRET assays
Vesicles were prepared as described above. Protein solutions were allowed to preincubate with 0.8 µM pY peptide for 10 min before addition of lipid vesicles. Vesicles were diluted with 30 mM Hepes pH 7.4 and 50 mM NaCl buffer, to give a final lipid concentration of 33 µg/ mL. A total of 4 µL of the lipid mixture was mixed with 4 µL of a varying concentration of protein constructs. The protein lipid mixture was allowed to equilibrate for 15 min. Reactions were measured using a PHERAStar HTS microplate reader (BMG Labtech) using a 280 nm excitation filter with 350 nm and 520 nm emission filters to measure Trp fluorescence and Dansyl-PS FRET emissions, respectively. The FRET signal is calculated as [(I-I0)/ I0], where I is the intensity at 520 nm, and where I0 is the intensity for a solution with lipid only (without protein). Binding curves were fit using a single-site binding model (GraphPadPrism).
Structural model of the mutant p110δ protein
A model of the E1021K mutant was made by starting with the structure of the wildtype enzyme (32) and then computationally mutating Glu at position 1021 to Lys, using the program Coot (33) and choosing the most common rotamer for the Lys residue. The nSH2 and iSH2 domains from the p110α/p85α complex have been superimposed on the p110δ/IC87114 complex. The cSH2 was modeled based on the p110β/p85β complex. The C-terminal helix, kα12, was modeled based on the p110γ structure.
Activation studies of the patient-derived T lymphocytes
PBMCs were separated by centrifugation of peripheral blood with a Histopaque 1077 gradient (Sigma) at 600 g for 20 minutes at room temperature. After cell counting and wash steps a negative MACS selection for CD14 cells (Miltenyi Biotec) was used to retrieve monocytes; the remaining lymphocytes were plated out in round-bottomed 96 well plates. Plates were pre-coated with 2.5µg/mL α-CD3 (OKT3) overnight at 4°C and washed prior to the addition of final concentrations of 3µM IC87114 (where appropriate) and 0.5 µg/mL α-CD28 (CD28.2). 2 x 10 5 lymphocytes were added per well. In other stimulation, CytoStim (Miltenyi Biotech) was added at a final concentration of 2µL/mL. Where indicated, IL-2 was added at final concentration of 20 ng/ml. After 48 hours stimulation, supernatants were retrieved and analyzed using a multiplexed FACS-based cytokine assay (Flow Cytomix, eBioscience) according to the manufacturer's instructions. Cells were stained with pre-titrated dilutions of FITC conjugated α-CD8 (G42-8), APC conjugated α-CD4 (RPA-T4) and fixable viability dye eFluor506 (eBioscience). Cells were analyzed on a BD LSRFortessa Flow Cytometer and data was analyzed in FlowJo (Tree Star). 
Isolation and stimulation of the patient-derived T and B lymphocytes

Western blotting
Stimulated T or B cells were lysed with ice-cold RIPA lysis buffer (Sigma) (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, and proteinase inhibitors) for 15 min. Lysates were centrifuged at 16,000 g for 10 min at 4°C. Proteins were incubated with laemmli sample buffer at 100°C for 5 min before being resolved on 10% Acrylamide/bis gels, transferred to PVDF membranes and probed with the following antibodies: p110δ (Santa Cruz, H-219, 1 in 2000 dilution); AKT (Cell Signalling, #9272S, 1 in 2000 dilution); pAKT S473 (Cell Signalling, #4060P, 1 in 2000 dilution); β-Actin (Sigma, A5441, 1 in 10,000 dilution).
PIP 3 quantification in the patient-derived T lymphocytes ex vivo
After stimulation of CD4+ or CD8+ T cells we terminated the reactions by addition of 750 µL kill solution (CHCl 3 :MeOH:1M HCl (10:20:1) and immediately froze the samples on dry ice. Samples were kept in a freezer at -80°C until they were processed. Samples were thawed and 1 ng of standard was added. After 5 min at room temperature we added 725 µL CHCl 3 and 170 µL 2M HCl to the samples, centrifuged them and collected the lower organic phase. We added pre-derivatisation wash 708 µL (upper phase of a CHCl 3 :MeOH:0.01 M HCl (8:4:3) mix), vortexed and centrifuged again and collected the lower phase in a fresh tube for derivatisation. We added 50 µL 2M TMS-diazomethane to the lipid extracts and incubated for 10 min at room temperature. The reaction was stopped by addition of glacial acetic acid and the samples were washed twice with 700 µL post-derivatisation buffer (upper phase of a CHCl 3 :MeOH:water (8:4:3) mix). After the final wash we added 100 µl of MeOH:H 2 O (9:1) to the samples and dried them under a stream of nitrogen at room temperature. Samples were then redissolved in 80 µl of MeOH, sonicated and 20 µl of water was added. The samples were then submitted to a mass spectrometry analysis, as described previously (16) . Samples were analyzed on a ABSciex QTRAP 4000 connected to a Waters Acquity UPLC system. Integrated area of PIP 3 was corrected for recovery against the internal standard and then normalized to cell number.
Studies of the patient-derived neutrophils
Neutrophils were isolated from blood by dextran sedimentation and density gradient centrifugation over 42% and 51% plasma/percoll gradients. Neutrophil lysates (20 µg/lane) were probed for the presence of p110δ and p85 using Abcam ab1678 (1 in 3000) and Millipore 06-195 (1 in 3000) respectively.
For PIP 3 measurements cells were primed with 10ng/ml TNFα for 60 min, incubated with 3µM IC87114 (or vehicle) for 10 min and stimulated with fMLP (100 nM) for 6 or 60 sec; reactions were stopped and PIP 3 measured as described. Superoxide release from TNFα-primed fMLP-stimulated neutrophils with or without 3µM IC87114 was measured by means the reduction of cytochrome C (1.2 mg/ml), as assessed by the change in optical density of the supernatants at 550 nm. To quantify the release of neutrophil elastase, cells were treated with either cytochalasin B (5 µg/ml for 10 min) or primed with TNFα (10 ng/ml for 60 min) and stimulated with fMLP (100nM for 10 min) with or without 3µM IC87114. The elastase activity present in the resulting supernatants was quantified by means of the EnChek® activity assay kit (Molecular Probes). Apoptosis (in the presence or absence of 1 ng/ml GM-CSF, with or without 3µM IC87114, was quantified at 20 h by annexinV/PI staining (FITC-Annexin V apoptosis detection kit, BD Pharminogen). Neutrophil chemotaxis in response to 100 ng/ml IL-8 was measured using NeuroprobeTM chemotaxis plates; migration of cells into the lower well was assessed at 90 min by cell counting.
FACS phenotyping of the patient-derived lymphocytes
Lymphocyte subset analysis was performed on whole blood after red cell lysis with optimized FITC, PE, ECD, PC5, PC7 labeled combinations of antibodies: CD3 (UCHT1), CD4 (4D11), CD8 (2D3), CD19 (J3.119), CD25 (B1.49.9), CD27 (1A4), CD28 (CD28.2), CD31 (5.6E), CD45 (J.33), CD45RA (2H4), CD56 (N901), CD127 (R34.34), all Beckman Coulter, CD27 (Dako), IgD (Southern Biotechnology), CD38, CD21 (BD Biosciences), IgM (Jackson Laboratories) at Papworth Hospital Immunology Laboratory. Data were acquired using Cytomics FC500 flow cytometers. Individual subsets were defined from viable lymphocytes gated using CD45/sidescatter (ss), CD3/ss, CD4/ss, and forward scatter/ss. Five thousand events were collected for each major analyte. Absolute counts were calculated comparing CD45/ss pan-leucogating and white cell counts (LH500, Beckman Coulter). Sequential gating defined B cell subsets in accordance with the Euroclass gating protocol (34) , and T cell subsets according to published gating strategies (7) (8) (9) .
Measuring cytokine production in whole blood stimulation assays Whole blood was diluted 1:5 with Rosewell Park Memorial Institute medium (RPMI) into 96-well F plates (Corning) and stimulated with IL-12 (20 ng/ml; R&D Systems; Abingdon), phytohemagglutinin (PHA; 10 µg/ml; Sigma-Aldrich), PAM2, PAM3, Imiquimod (1micg/ml Invivogen), and LPS (1 µg/ml) List Biochemicals. Supernatants were taken at 24h. Cytokines were measured using standard ELISA according to the manufacturer's recommendations (IFN-γ), or using a Bio-Plex system (IL-6, and IL-12; Bio-Rad)
Cloning of human p110δ
Human p110δ cDNAs were cloned into the MIGR1 retroviral vector using HpaI and XhoI restriction sites. E1021K and D911A mutations were introduced by site directed mutagenesis. For retroviral transduction, virus was prepared using Plat-E packaging cell line.
p110δ-knockout mice
Mice with deletion of p110δ (p110δ KO ) have been described before (35) . Mice were maintained under specific pathogen-free conditions. All protocols involving live animals were approved by the United-Kingdom Home Office and institutional ethical review committees.
Transduction of T cell blasts from the p110δ
KO mice p110δ KO T cell blasts were obtained by stimulating whole lymph node cell suspension with anti-CD3 mAb (2C11 clone at 1 µg/ml) and recombinant human IL-2 (20 ng/ml) for 2 days. 24h before the transduction, 6-well non-tissue culture were coated with Retronectin (Takara Bio inc., Japan) at 50 µg/ml in PBS overnight at 4°C. After removing the Retronectin, the plates were blocked in PBS+0.5%BSA at room temperature for 30 min. The virus-containing supernatant was added to the plate and centrifuged at 2000 g at 32°C for 90min. After discarding the supernatant the same procedure was repeated with a second aliquot. P110δ KO T cell blasts (2 x 10 6 ) in culture media with IL-2 were added to the virus-coated plate and centrifuged at 500 g for 30 min. Cells were used 2-4 days after the transduction. Typically between 20% and 30% of cells were transduced (GFP positive cells detected by FACS).
Western blot analysis of the transduced T cell blasts from the p110δ
KO mice Transduced p110δ KO T cell blasts were incubated with anti-CD3 (2C11 at 1 µg/ml) and anti-CD28 (37.51 at 2 µg/ml) mAb on ice for 30 min. Cells were washed once in ice-cold RPMI, incubated 2 min at 37°C and then stimulated with goat anti-hamster IgG (Jackson ImmunoResearch Laboratory) for 5 min. Cells were lysed in ice-cold lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM NaF, 10 mM iodoacetamide, 1% NP-40, 1 mM PMSF and protease inhibitors) for 10min and the lysates were centrifuged at 16000 g for 10min at 4°C. Proteins were resolved on NuPage 4-12% BisTris gels (Invitrogen), transferred to PVDF membranes and probed with the indicated antibodies.
Antibodies used for Western-Blot were from Cell Signaling Technology (Danvers, MA) unless otherwise specified: anti-pAKT Thr308 (4056), anti-AKT1 (2967), anti-pErk1/2 (4377), anti-pFoxO1(Thr24)/FoxO3a(Thr32) (9464), anti-p110δ (Santa-Cruz, sc-7176), anti-pS6 (4858S), anti-βactin (Santa-Cruz, sc-47778).
Analysis of Somatic hypermutation (SHM)
Peripheral blood CD19+ CD27+ cells were sorted and processed to obtain cDNA. PCR was performed using VH3-23 and Cµ primers. The DNAs were then cloned and sequenced as described previously (36) .
Supplementary Text
Clinical and laboratory presentation of APDS patients
All APDS patients suffered recurrent and often severe oto-sino-pulmonary infections, with frequent isolates of Streptococcus pneumoniae and Haemophilus influenzae (table S2 and table 1) . In most cases, there was radiological evidence of progressive large or small airway damage, i.e. bronchiectasis and/or mosaic attenuation, which developed in childhood ( fig. S1 ). Lung and lymph node biopsies taken from P9 at the age of 2 years revealed extensive non-clonal lymphoid hyperplasia, consistent with an immunodeficiency. Severe infection with members of the Herpesvirus family occurred in four patients, and a sibling of P5 and P6, who died at the age of 12 years, reputedly of Varicella zoster pneumonitis. Most patients had splenomegaly, often detected prior to the onset of recurrent infections. P3 and P9 developed massive mediastinal lymphadenopathy leading to airway obstruction and distal collapse. Autoimmune hemolytic anemia was observed in two patients (P15 and P16 in family G); other patients had no autoimmune manifestations.
Immunologically, we found T cell lymphopenia (182-790 cells/µl) and/or reduction of circulating CD4+ and CD8+ T cells, as well as progressive B cell lymphopenia (0-100 cells/µl). The numbers of neutrophils, basophils, eosinophils, monocytes and NK cells in peripheral blood were normal. Increased IgM levels (2-21 g/l) were usually observed, although normal IgM levels were also recorded. While total circulating IgG levels were normal in most patients, decreased IgG2 levels (0.04-1.17 g/l) were found in 10 out of 11 patients tested. Six patients had reduced IgA (0-0.3 g/l); other 11 patients had normal IgA levels.
Responses to tetanus vaccination were normal in most patients. The patients had reduced antibody responses following pneumococcal (Prevnar 13 and Pneumovax 23) vaccinations (3-12 mg/l total and <0.35 mg/l against 7-12 out of the 12 serotypes tested), as well as H. influenzae type B (Hib) vaccination (0.1-0.5 mg/l). Low titers of isohemagglutinin antibodies were found. Taken together, these data suggest that APDS patients have deficient antibody production against polysaccharide antigens.
We studied lymphocyte populations and found increased numbers of circulating transitional B cells (CD19+ CD38+ IgM+), reduced numbers of classswitched memory B cells (CD19+ CD27+ IgD-), expansion of CD25-CD127-populations among both CD4+ and CD8+ T cells, reduction of naïve (CD8+ CD45RA+ CCR7+) and expansion of effector memory (CD8+ CD45RA-CCR7-) T cells (table S2) . Stimulation of whole blood with LPS or LPS/IL-12, but not with PHA, revealed reduced IFN-γ production in the patients (fig. S2 ). Patients also showed higher production of IL-12 in response to LPS/IFNγ stimulation ( fig. S2) . Innate IL-6 induction by various TLR agonists was slightly increased or normal. Frequency of somatic hypermutation (SHM) was studied in two patients and was found to be normal (4.4% and 3.2% in P14 and P16 respectively; normal range: 2.3 -6.5%).
Of note, patients P5 and P6 in Family B were first reported over 30 years ago, although the causative mutation remained unknown (37) . The Waardenburg's syndrome was considered as a possible diagnosis because of partial deafness and white forelock present in the elder family members (but not P5 or P6). In the exome sequence data of P5 (subject IV.2 or Case 9 in (37)) rare mutations in genes associated with Waardenburg's syndrome (PAX3, MITF, EDNRB, EDN3, SOX10) were not found. This suggests that his hearing impairment is likely to have been secondary to recurrent ear infections that P5 experienced since early childhood. Given that patients in other families had no evidence of hair depigmentation, its cause in the deceased members of family B remains unknown, but is unlikely to be related to the E1021K p110δ mutation.
Fig. S1. Bronchiectasis and mosaic attenuation in APDS patients
Representative Computed Tomography images demonstrating the radiographic features of bronchiectasis in patient P6 aged 34 years (upper, arrow), and mosaic attenuation in patient P7 aged 5 years (lower, circled).
Fig. S2. Cytokine production in the whole blood stimulation assays
Patients (N=5, red squares) from families A and C were tested in two independent whole blood in vitro stimulation assays. Production of IFN-γ (A), IL-6 (B) and IL-12 (C) were measured after indicated stimulations and compared to controls (N=30, blue circles). A paired sample of a "travel control" was tested with each patient's sample. Data from 25 additional controls obtained under same conditions are also shown. Data were normalised on lymphocyte count to correct for lymphopenia. Black bars show the mean. P-values were calculated using a Mann-Whitney U test with Bonferroni correction. Only P-values <0.05 are shown.
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Fig. S3. Enhanced PI3 kinase activity of the mutant p110δ E1021K protein in vitro
A. SDS PAGE, Coomassie-stained gel of recombinant wild-type and E1021K mutant p110δ/p85α complexes. B. Basal PI3K activity of the p110δ/p85α complexes as a function of p110δ concentration. Data are mean ± SD of 3 independent experiments. C. Basal and pY-stimulated PI3K activity of the p110δ/p85α complexes as a function of p110δ concentration. Data are mean ± SD of 3 independent experiments.
Fig. S4. Increased levels of phosphorylated AKT protein in T-cell blasts of the p110δ-knockout mice expressing the mutant p110δ E1021K protein
Representative (of N=2) Western blot showing levels of proteins in T-cell blasts of the p110δ-knockout mice transduced with retroviral constructs and expressing either GFP or wild-type p110δ (p110δ WT ) or kinase dead p110δ (p110δ D911A ) or p110δ E1021K without stimulation (-) or after stimulation (+) with anti-CD3 antibodies and anti-CD28 antibodies.
Fig. S5. APDS patients have enhanced stimulated-induced T cell death that is not prevented by IL-2
A. Representative FACS plots of lymphocytes from a healthy control (upper panels) and a patient (lower panels). Left panels show side/forward scatter characteristics in unstimulated cells. Centre and right panels show side/forward scatter plots and viability dye staining respectively following lymphocyte stimulation by plates coated with 2.5 µg/mL anti-CD3 antibodies and 0.5 µg/mL soluble anti-CD28 antibodies (α-CD3/28) for 48 hours.
B. Quantification of surviving CD4+ and CD8+ T cells as indicated by % of cells excluding viability dye. Cells of patients (red, N=3) and controls (blue, N=5) were studied without stimulation and after stimulation with anti-CD3/anti-CD28 antibodies and in the presence of IL-2. Each subject was studied in triplicate. The data show mean +/-SEM. P-values were calculated using Student's t test.
A B Fig. S6. APDS patients have reduced T cell cytokine production after anti-CD3/anti-CD28 stimulation
Cytokine concentrations in lymphocyte culture supernatants following 48 hour culture with anti-CD3 and anti-CD28 stimulation with plate-bound antibodies and in the presence or absence of exogenous IL-2. Levels of IL-2 were not measured when exogenous IL-2 was added. Data for patients (red squares, N=3) and controls (blue circles, N=5) are shown. Red and blue horizontal bars show mean concentrations for patients and controls respectively.
Fig. S7. APDS patients have reduced T cell cytokine production after CytoStim stimulation
Cytokine concentrations in lymphocyte culture supernatants following 48 hour culture with CytoStim. Data for patients (red squares, N=3) and controls (blue circles, N=5) are shown. Red and blue horizontal bars show mean concentrations for patients and controls respectively. 
Fig. S9. Analyses of neutrophils in APDS patients and controls
Panel A. PI3Kδ in neutrophils. Representative (of N=3) Western blot of neutrophil lysates from patient and healthy age-matched control probed for PI3Kδ and p85.
Panel B. Neutrophil PIP 3 generation. To allow for the possible confounding effect of chronic sepsis we studied cells prepared in parallel from age-matched patients with bronchiectasis, as well as from healthy controls. Neutrophils purified from peripheral blood of patients, healthy controls and disease controls were primed with 10 ng/ml TNFα and treated with 3 µM IC87114 or vehicle prior to stimulation with 100 nM fMLP for 6 s or 60 s. PIP 3 was quantified as described in 'Methods'. Data are expressed as fold-upregulation relative to healthy control baseline value and represent mean ± SEM of 3 independent experiments each performed in duplicate.
Panel C. Neutrophils were isolated from the peripheral blood of patients, healthy controls and disease controls and assessed for following functional integrity. Cells were stimulated with 10 ng/ml PMA or 10ng/ml TNFα plus 100 nM fMLP in the presence or absence of 3 µM IC87114 and extracellular release of superoxide was quantified by the reduction of cytochrome C. A single experiment representative of N=2 is shown.
Panel D. Neutrophils were stimulated with 5 µg/ml cytochalasin B, or with 10 ng/ml TNFα plus 100 nM fMLP in the presence or absence of 3 µM IC87114; neutrophil elastase release was quantified by cleavage of DQ-elastin; N=1 performed in triplicate.
Panel E. Neutrophils were cultured for 20 h in the presence of 1 ng/ml GM-CSF and/or 3 µM IC87114 as indicated and apoptosis was assessed by AnnexinV/PI staining; N=2 performed in duplicate.
Panel F. Neutrophil chemotaxis was assessed using NeuroProbe microplates. Migration of neutrophils towards 100 ng/ml IL-8 placed in the lower chamber was assessed at 90 min by cell counting (N=1 experiment performed in duplicate). 
